Keyphrases
Incidence Rate
100%
Randomized Trial
100%
Confidence Interval
100%
Meta-analysis
100%
Direct Oral Anticoagulants
100%
Patients with Cardiovascular Diseases
100%
Dual Pathway Inhibition
100%
Placebo
40%
Antiplatelet Therapy
30%
Dual Antiplatelet Therapy
30%
Bleeding
20%
Randomized Controlled Trial
20%
Ischemic Events
20%
Twice Daily
20%
Major Bleeding
20%
Ultra-low Dose
20%
Cardiovascular Mortality
20%
Bleeding Risk
20%
Subgroup Analysis
20%
Rivaroxaban
20%
Major Adverse Cardiovascular Events
20%
Stroke Prevention
20%
Bleeding Incidence
20%
Myocardial Infarction
10%
Regression Analysis
10%
Intracranial Hemorrhage
10%
Safety Endpoints
10%
Follow-up Interval
10%
Total Mortality
10%
Antiplatelet Agents
10%
Systematic Meta-analysis
10%
Dosing Regimen
10%
Stroke Incidence
10%
All-cause Mortality
10%
Prospero
10%
Efficacy Endpoint
10%
Primary Safety
10%
Number-needed-to-treat
10%
Overall Safety
10%
Number Needed to Harm
10%
Fatal Bleeding
10%
Medicine and Dentistry
Cardiovascular Disease
100%
Meta-Analysis
100%
Direct Oral Anticoagulant
100%
Low Drug Dose
90%
Apoplexy
50%
Antiplatelet
50%
Placebo
40%
Bleeding
20%
Cardiovascular System
20%
Randomized Controlled Trial
20%
Major Bleeding
20%
Subgroup Analysis
20%
Rivaroxaban
20%
Myocardial Infarction
10%
Cerebral Hemorrhage
10%
Systematic Review
10%
Antiplatelet Drug
10%
Cause of Death
10%
Meta-Regression
10%
Drug Dose Regimen
10%
Numbers Needed to Treat
10%
Ciclonicate
10%
Number Needed to Harm
10%
Pharmacology, Toxicology and Pharmaceutical Science
Direct Oral Anticoagulant
100%
Cardiovascular Disease
100%
Cerebrovascular Accident
50%
Antiplatelet
50%
Placebo
40%
Bleeding
40%
Randomized Controlled Trial
20%
Rivaroxaban
20%
Heart Infarction
10%
Brain Hemorrhage
10%
Antithrombocytic Agent
10%
Cause of Death
10%
Number Needed to Treat
10%
Ciclonicate
10%
Number Needed to Harm
10%